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The sialic acid content of erythrocytes from healthy individuals of different 
blood types and of patients with known hematological disorders has been 
determined. The sialic acid was completely released enzymatically with 
sialidase and quantitated by the thiobarbituric acid method. The sialic acid 
content of erythrocytes was constant irrespective of ABO blood type, or 
anticoagulant used; viz, 0.85—0.92 ^moles/ml of packed erythrocytes or 
46—53 X 106 sialyl residues per cell. Deviations from these normal values 
were obtained with erythrocytes from patients with a variety of hematological 
disorders. Patients with the following disorders have significantly (P < 0.01) lower 
sialic acid values compared to erythrocytes from healthy individuals (given 
in the order of decreasing sialic acid content): sickle cell anemia, acute lymphocytic 
leukemia, chronic lymphocytic leukemia, acute myelomonocytic leukemia, 
non-Hodgkin lymphocytic lymphoma, chronic granulocytic leukemia, acute 
myelocytic leukemia, leukemia, and Hodgkin disease. 
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INTRODUCTION 
Sialic acid has been detected on the surface of erythrocytes of all species examined, 
including man [1—4]. The type and amount of sialic acid vary appreciably in the different 
species; eg, in the dog there are 72 X 106 sialyl residues/erythrocyte, whereas in the rabbit 
there are 3 X 106 residues/erythrocyte [4] . 
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It has now been shown in a number of laboratories that the removal of the sialyl 
residues results in a loss of viability of the erythrocytes in circulation as demonstrated 
by 51Cr-labeling studies [see reference 4 for review of literature]. We have extended these 
observations to show that it is true of a number of mammalian species irrespective of the 
type or amount of sialic acid present [4]. Since the phenomenon is not observed with 
chicken erythrocytes [4], it can be assumed that the sequestration of asialo-erythrocytes 
involves a specific mechanism and is not merely due to the loss of the overall total nega­
tive charge of the erythrocyte. 
We have further shown that in the dog, removal of approximately 10% of the total 
sialic acid is sufficient to result in almost complete sequestration of the asialo-erythrocytes 
[4]. The threshold value of 10% obtains added significance in light of previous observations 
that young erythrocytes contain 10—15% more sialic acid than old erythrocytes [5, 6] . We 
therefore subscribed to the hypothesis that the sialic acid of erythrocytes is physiologically 
involved in the maintenance of erythrocytes in circulation and any drop from the threshold 
number of residues per erythrocyte might represent the signal for the sequestration of the 
effete erythrocytes from circulation. It was to ascertain the validity of this hypothesis that 
the following survey was undertaken to determine the constancy of the sialic acid content 
of erythrocytes in healthy individuals and to look for possible divergence in hematological 
disorders. A preliminary report has already appeared [7]. 
MATERIALS AND METHODS 
The sialidase used for these investigations was prepared and assayed as previously 
described [4]. In that study we had demonstrated that, under the conditions of assay, 
the sialic acid released represented the total bound sialic acid present on the red cell 
surface. 
Blood from normal individuals and from patients was obtained in accordance with the 
University Hospital guidelines and accreditation regarding "Research Projects Involving 
Human Subjects." 
Blood from healthy individuals represented the blood obtained from University Hos­
pital staff and volunteer blood donors with no known hematological disorders. Patient 
blood samples were obtained from a random selection of patients with hematological dis­
orders attending the Hematology-Oncology Clinic, University of Michigan Medical Center. 
In all cases venous blood was drawn into Vacutainers (Becton-Dickinson, Orangeburg, NY), 
usually with EDTA* or heparin as the anticoagulant. Samples were stored for no longer than 
24 hours at 4°C and assayed as previously described, with care taken that the buffy coat was 
completely removed [4]. The results can be expressed either as μτηοΐεβ of sialic acid per ml 
of packed erythrocytes, or as number of sialic acid residues per erythrocyte. 
RESULTS 
Optimal Conditions for the Release of Sialic Acid 
Although the conditions for optimal release of sialic acid have previously been estab­
lished for animal erythrocytes, they have been repeated here to reconfirm their applicabil­
ity to human erythrocytes (Figs. 1 and 2). 
Abbreviations: ACD = acid citrate dextrose ; CPD = citrate phosphate dextrose ; DF = degrees of freedom ; 
EDTA = ethylenediamine tetra-acetate; SD = standard deviation. 
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Fig. 1. Release of sialic acid from hyman erythrocytes as a function of sialidase concentration. One-
fifth ml of packed erythrocytes was incubated at 37° for 30 minutes with varying amounts of enzyme 
under the standard assay conditions. 
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Fig. 2. Release of sialic acid from human erythrocytes with sialidase as a function of time. Four-
hundredths of a unit of sialidase were incubated with 0.2 ml of packed erythrocytes at 37° for 
varying periods of time. 
Effect of Anticoagulant 
A number of different anticoagulants were used: heparin, ACD, CPD and EDTA. 
Blood from one individual was collected into each of the different anticoagulants. The sialic 
acid content was determined on the first day and after four days of storage at 4°C. Similar 
experiments were performed with blood of different species. The erythrocytes were then 
centrifuged and washed in an identical manner, and the sialic acid content of the erythro­
cytes was determined. No difference was found in the sialic acid content of the different 
specimens stored in the different anticoagulants (Table I). 
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Effect of Storage of Blood Under Blood Bank Conditions 
A half unit of blood was withdrawn from each of two volunteers and collected in 
CPD plastic packs. The units were stored in a refrigerator and subjected to the routine 
manipulation of blood stored in a blood bank. Aliquots of blood were removed at regular 
intervals over a period of three weeks, and the sialic acid content of the erythrocytes was 
determined. Figure 3 shows the typical curves obtained. There is a rapid initial loss of sialic 
acid in the first 24 hours, which then stabilizes over the next three weeks (Fig. 3A and B). 
With care in handling, this initial loss of sialic acid can be greatly diminished. 
Sialic Acid Content of Erythrocytes From Individuals of Different ABO Blood Types and 
Patients With Certain Hematological Disorders 
Table II and Figure 4 show the detailed distribution of sialic acid content of erythro­
cytes from 65 healthy individuals and 121 patients. In some patients (22/121) blood was 
available for analysis on more than one occasion. There was no appreciable change in the 
sialic acid content in most cases. There were a few exceptions to this generalization where 
the sialyl residues/erythrocyte varied by more than 5%; eg, two patients with Hodgkin disease 
with values ranging from 39.7 to 43.9 X 106 and 42.5 to 45.0 X 106, respectively; 41.2 to 
44.8 X 106 in one acute myelomonocytic leukemia patient, and 44.9 to 48.9 X 106 in a 
patient with non-Hodgkin lymphocytic lymphoma. A wide distribution of sialic acid con­
tent is observed over the spectrum of hematological disorders. But if we use the interval 
determined by the mean ± 2 SD of the sialic acid values of normal blood as the "healthy" 
range, then distinct categories become apparent (Table II, Fig. 4). 
The mean sialic acid content on erythrocytes of patients with hematological disorders 
was compared to the mean found in the erythrocytes of healthy individuals by applying 
a two-tailed t-test* for equal population means with a 0.01 level of significance [8 ] . The 
results (Table II) show that all of the disorders, with the exception of erythroleukemia, ag-
nogenic myeloid metaplasia, idiopathic thrombocytopenic purpura, subacute granulocytic 
leukemia, multiple myeloma, and autoimmune hemolytic anemia had sialic acid means that 
The hypothesis that the population means are statistically identical is accepted whenever the critical 
Student's t-value is greater than the calculated (positive) t-value. Conversely, this hypothesis is rejected 
whenever the critical t-value is less than the experimental value. 
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Fig. 3. Sialic acid content of human erythrocytes stored under blood bank conditions. One half unit 
of blood was drawn from two individuals of blood types A (3A) and 0 (3B) by standard hospital pro­
cedure. Blood was stored in CPD at 4 under standard blood bank conditions. Samples of the well 
mixed blood were withdrawn over a three week period and the washed cells assayed for their sialic acid 
content in the usual manner. 
differed significantly from those of healthy individuals. Furthermore, all but idiopathic 
thrombocytopenic purpura and agnogenic myeloid metaplasia erythrocytes differed from 
normal at P < 0.05. The magnitude of the differences between the means is a useful objec­
tive measure for comparison. 
DISCUSSION 
As is apparent from Figures 1 and 2, under the conditions of the assay we measure the 
total sialic acid that can be released with sialidase. We have previously shown [4] that this 
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Fig. 4. Distribution of sialic acid content in erythrocytes of healthy individuals of blood type A, B, AB 
and O as well as from patients with certain hematological disorders. The rectangular box represents the 
mean ± S.D. The enclosed circles represent_the observed high and low values for each distribution. The 
95% normal range for healthy individuals X ± 2 (S.D.). 
is indeed a measure of the total sialic acid on the erythrocyte surface. Furthermore, the 
anticoagulant used to collect and store the blood does not affect the determination of the 
total sialic acid on the erythrocyte surface. A certain amount of erythrocyte surface sialic 
acid is lost during storage in the anticoagulants, which in citrate/phosphate/dextrose becomes 
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TABLE II. Sialic Acid Residues X 10 /Erythrocyte 
Designation 
Healthy type A 
Healthy type B 
Healthy type AB 
Healthy type 0 





















































































































































































aThe calculated t-value of those populations of diseased cells that are significantly different from the 
population of healthy cells using a two-tailed t-test for population are underlined. 
quite marked when the blood is drawn and stored under conditions of the blood bank 
(Figs. 3A and B). The experiments described here were therefore performed with fresh blood 
obtained from healthy individuals and patients and assayed within 24 hours. 
The values for sialic acid content of erythrocytes in any given individual remain remark­
ably constant on repeated determination. However, there is usually more variation between 
individuals in sialic acid content of erythrocytes. Using approximately 95% limits gives a. 
normal range of 46-53 X 106 sialyl residues per erythrocyte for healthy individuals. 
Changes in the sialic acid content of erythrocytes can be attributed to 1) variation in 
the sialic acid content present at the end of the oligosaccharide chains of the glycoconjugates, 
2) changes in the type and amount of sialoglycoconjugates in the erythrocyte membrane, 
and/or 3) extension or diminution of the erythrocyte membrane consisting of sialoglyco­
conjugates, proteins, and lipids, thereby affecting the analytical value of sialic acid content 
per erythrocyte as well as the other carbohydrate components [9, 10]. 
Examples of 1) have been observed in viral infection with the myxo-influenza group 
of viruses when the infection is accompanied by a loss of erythrocytes from the circulation 
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[11, 12]. The second type is illustrated by studies on individuals who are En(a—), where 
the sialic acid content of the erythrocytes has been shown to be as low as 33% of normal 
[13]. The red cells of these individuals appeared to have a normal survival time in circulation. 
This would be seemingly incompatible with the hypothesis proposed [4] that a low sialic 
acid content would result in the loss of viability. Electrophoretic analysis of the erythro-
cyte membranes of En(a—) individuals, however, demonstrated almost total absence of a 
specific sialo-glycoprotein, glycophorin A [14]. Thus, in this phenotype, even though the 
number of sialyl residues on the erythrocyte surface is decreased, there is no increase in 
the number of oligosaccharide stubs terminating in galactosyl residues, a requirement of 
the hypothesis for more rapid sequestration from circulation [4]. 
Low erythrocytic sialic acid levels have previously been observed in diabetes mellitus 
patients, and it has been claimed that this low level can be brought back to normal values 
by treatment with insulin [15] in paroxysmal nocturnal hemoglobinuria [16], sickle cell 
anemia [17], and thalassemia [18, 19]. 
Erythrocyte membrane of thalassemic patients has been reported to have 25% less 
sialic acid than that found in normals. Kahane et al subsequently demonstrated that the 
young erythrocytes released from the bone marrow have close to normal sialoglycoproteins 
and that old thalassemic erythrocytes have 50% of their sialic acid [20]. 
Studies are underway in our laboratories to determine the causes of the low and high 
sialic acid content of erythrocytes in certain of the above discussed hematological disorders. 
CONCLUSIONS 
1) Optimal conditions for the collection of blood and determination of the total 
sialic acid of erythrocytes are presented. 
2) The normal range of sialic acid residues per erythrocyte in 65 healthy individuals 
is 49.7 X 106 ± 1.7, irrespective of ABO blood type. 
3) From the limited number of patients with hematological disorders examined, we 
have found that the range of sialic acid residues per erythrocyte varies from higher than 
normal in erythroleukemics (53.4 X 106 ± 0.3), and from significantly lower than normal 
(P < 0.01) in the following disorders, given in the order of decreasing sialic acid content: 
sickle cell anemia (48.3 X 106 ± 1.8), acute lymphocytic leukemia, chronic lymphocytic 
leukemia, acute myelomonocytic leukemia, non-Hodgkin lymphocytic lymphoma, chronic 
granulocytic leukemia, acute myelocytic leukemia, leukemia, and Hodgkin disease (43.8 
X 106 ±2.1). 
More in-depth investigations of the cause(s) of low sialic acid content in certain hema­
tological disorders are under way. 
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